Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Key facts

Sponsor

Asociación para Evitar la Ceguera en México

Principal Investigator

Maria Martínez-Castellanos, MD

Asociación para Evitar la Ceguera en México

Intervention

intravitreal injection(drug)

Eligibility

All sexes

Timeline

2007 – 2024

Study locations (1)

• Asociación para Evitar la Ceguera en México Hospital "Luis Sanchez Bulnes", Mexico City, Mexico DF, Mexico

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Retinopathy of prematurity

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07093255
  Safety, PK and PD of FLQ-101 in Premature Neonates
  FELIQS INC.
• RECRUITINGNCT06612541
  Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNANCT07334652
  Pain and Comfort in the Examination of Retinopathy of Prematurity
  Ataturk University
• RECRUITINGNANCT06717412
  Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
  Wang Yusheng
• RECRUITINGNCT05558059
  Imaging Retinal Vasculature in Infant Eyes
  Duke University
• ACTIVE NOT RECRUITINGNANCT06109285
  Validation of i-ROP DL to Detect More Than Mild ROP
  Siloam Vision
• RECRUITINGNCT06315556
  An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
  Bayer
• RECRUITINGNANCT06694103
  The Effect of Two Non-Pharmacological Methods on Pain During Retinopathy Examination
  Sinem Basdemir

See all trials for Retinopathy of prematurity →